Collegium Pharmaceutical, Inc. (COLL) Net margin 2016–2025
Collegium Pharmaceutical, Inc. (COLL) net profit margin by fiscal year — reported net income divided by reported revenue.
8.1%FY2025 · since FY2016: -5504.1% → 8.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 8.1% | -2.9 pp |
| FY2024 | 11.0% | +2.5 pp |
| FY2023 | 8.5% | +13.9 pp |
| FY2022 | -5.4% | -31.2 pp |
| FY2021 | 25.8% | +17.2 pp |
| FY2020 | 8.6% | +16.3 pp |
| FY2019 | -7.7% | +6.3 pp |
| FY2018 | -14.0% | +249.0 pp |
| FY2017 | -262.9% | +5241.2 pp |
| FY2016 | -5504.1% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More COLL financial trends
COLL RevenueCOLL Net incomeCOLL Gross profitCOLL Gross marginCOLL Operating incomeCOLL Operating marginCOLL Operating cash flowCOLL Free cash flowCOLL Capital expendituresCOLL Return on equityCOLL Stock buybacksCOLL Dividends paidCOLL Total assetsCOLL Total liabilitiesCOLL Shareholders’ equityCOLL overview →